Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Investing in stocks with high valuations isn't necessarily a bad decision, but it's something to be done deliberately and with caution. As the creator of the blockbuster weight-loss drug Zepbound, and ...

"We know the supply chain, PBMs are not transparent enough and we should be able to pass through more of that savings directly to consumers," Eli Lilly CEO David Ricks said during a presentation ...

Plus: How AI propelled Nvidia up the list and other insights from this year's survey of corporate reputations.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital Technology Officer (CDTO), reporting to Group CEO, Thomas Schinecker ...

"We actually believe that we have an oral here that could generate the same amount of weight loss as you see with Wegovy or Ozempic, but in a pill," Jonsson added, echoing what Eli Lilly CEO Dave ...

Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound ... 21.1% after 36 weeks. Kailera CEO Ron Renaud reiterated ...

Earlier this month, Eli Lilly CEO David Ricks stated in a Bloomberg TV interview that the company’s experimental weight-loss pill, orforglipron, could receive regulatory approval as early as ...